TWi to Sell Generic Versions Of Megace ES, Lidoderm in U.S.

Taiwan-based generic drug maker TWi Pharmaceuticals said Feb. 23 that it will sell two generics on the U.S. market that originally would have been sold by Israel-based Teva.

TWi announced that it reached an agreement with Teva that will transfer the U.S. sales and distribution rights of generic versions of Megace ES (megestrol acetate oral suspension, 625 mg/5 ml) and Lidoderm (lidocaine patch, 5 percent) from Teva to TWi.

The brand version of Megace ES is made by Par Pharmaceuticals Inc. and is used to treat anorexia, cachexia and unexplained weight loss in patients with HIV and AIDS. The brand ...